Regulatory Press Releases
PILA PHARMA ENTERS INTO AGREEMENT WITH THE CRO GUBRA ON PRECLINICAL TRIALS OF XEN-D0501 IN OBESITY
Malmö, 30 September 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest in the space, that it has signed a contract with Danish preclinical Contract Research Organisation, Gubra. The aim is to demonstrate preclinical proof-of-concept of PILA PHARMA's proprietary…
PILA PHARMA PUBLISHES INTERIM REPORT (1 JANUARY – 30 JUNE 2025)
Malmö, 27 August, 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, today publishes the Company´s interim report for the period January - June 2025. The report can be found on the Company's website: https://pilapharma.com/financial-reports/ SUMMARY OF INTERIM REPORT First Half year (1 January -…
PILA PHARMA ANNOUNCES THE COMPLETION OF REGISTRATION OF SHARES IN THE RIGHTS ISSUE AND ITS ASSOCIATED DIRECTED ISSUES, MARKING THE END OF THE RIGHTS ISSUE PROCESS
Malmö, 21 August 2025 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announced on 23 July 2025 that the rights issue of units that was resolved by the board of directors, subject to the annual general meeting's authorization held on 29 April 2024 (the "Authorization"), on 19 June (the "Rights Issue") was completed. In connection to the Rights Issue,…
PILA PHARMA announces updated dates for last day of trading with paid subscribed units and first day of trading in new shares
Malmö, 31 July 2025 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announces that the last day of trading in paid subscribed units (Sw. BTU) in connection with the Company's rights issue of units which the Board of Directors resolved on 19 June 2025, with the authorization from the annual general meeting held 29 April 2025 (the "Rights Issue"),…
The board of directors of PILA PHARMA has resolved to carry out a directed issue of units to underwriters in the previously ended rights issue
Malmö, 23 July 2025 THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION…